4.85
price up icon5.21%   0.24
after-market Dopo l'orario di chiusura: 4.86 0.01 +0.21%
loading
Precedente Chiudi:
$4.61
Aprire:
$4.61
Volume 24 ore:
591.88K
Relative Volume:
0.21
Capitalizzazione di mercato:
$61.31M
Reddito:
-
Utile/perdita netta:
$-30.54M
Rapporto P/E:
-3.129
EPS:
-1.55
Flusso di cassa netto:
$-18.30M
1 W Prestazione:
+4.30%
1M Prestazione:
-30.12%
6M Prestazione:
+702.98%
1 anno Prestazione:
+1,088%
Intervallo 1D:
Value
$4.60
$4.96
Intervallo di 1 settimana:
Value
$4.38
$4.96
Portata 52W:
Value
$0.202
$8.2457

Unicycive Therapeutics Inc Stock (UNCY) Company Profile

Name
Nome
Unicycive Therapeutics Inc
Name
Telefono
650-384-0642
Name
Indirizzo
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Name
Dipendente
22
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-31
Name
Ultimi documenti SEC
Name
UNCY's Discussions on Twitter

Confronta UNCY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
UNCY
Unicycive Therapeutics Inc
4.85 58.86M 0 -30.54M -18.30M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-21 Iniziato Guggenheim Buy
2024-04-04 Iniziato Piper Sandler Overweight

Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie

pulisher
Jul 24, 2025

Unicycive Therapeutics: Manageable CMC Speed-Bump—Pill-Burden Edge Intact, Buying Opportunity Pre-FDA Decision - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

Unicycive Therapeutics: Manageable CMC Speed BumpPill Burden Edge Intact, Buying (UNCY) - Seeking Alpha

Jul 24, 2025
pulisher
Jul 24, 2025

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

Revolutionary Kidney Disease Drug Shows 90% Success Rate with Just 3 Pills Daily, New Study Reveals - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

Is Unicycive Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Unicycive Therapeutics Inc. stock priceMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Unicycive Therapeutics Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc.UNCY - WV News

Jul 22, 2025
pulisher
Jul 22, 2025

Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Unicycive Therapeutics Inc. stockExceptional market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

Best Stocks for a Post COVID Recovery in India Financial Expert RecommendationsFree Stock Market Trend Analysis - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Palladyne AI Corp. stockRapid growth trajectories - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Jul 19, 2025
pulisher
Jul 19, 2025

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Jul 19, 2025
pulisher
Jul 19, 2025

UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - Business Wire

Jul 19, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 04:29:16 - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Why Unicycive Therapeutics Inc. stock is on top investor watchlistsDaily Top Gainers - Newser

Jul 17, 2025
pulisher
Jul 15, 2025

Why Unicycive Therapeutics Inc. stock attracts strong analyst attentionFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Unicycive Therapeutics Inc. stock performs during market volatilityReal Chart Play - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Unicycive Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Transcript : Unicycive Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 11 - MarketScreener

Jul 14, 2025
pulisher
Jul 13, 2025

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - 富途牛牛

Jul 13, 2025
pulisher
Jul 12, 2025

Pomerantz LLP Investigates Unicycive Therapeutics Securities Fraud Claims. - AInvest

Jul 12, 2025
pulisher
Jul 09, 2025

Unicycive Regains Nasdaq Compliance After Stock Split - The Globe and Mail

Jul 09, 2025
pulisher
Jul 09, 2025

Unicycive regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Unicycive regains Nasdaq compliance after reverse stock split - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Unicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price Recovery - Quiver Quantitative

Jul 08, 2025
pulisher
Jul 08, 2025

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Unicycive Successfully Maintains Nasdaq Listing Following 1:10 Reverse Stock Split - Stock Titan

Jul 08, 2025
pulisher
Jul 08, 2025

Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World

Jul 08, 2025
pulisher
Jul 07, 2025

Unicycive Therapeutics to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference - Nasdaq

Jul 07, 2025
pulisher
Jul 07, 2025

Clinical-Stage Kidney Disease Biotech Unicycive Reveals Latest Therapeutic Progress at Major Healthcare Conference - Stock Titan

Jul 07, 2025
pulisher
Jul 03, 2025

Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 02, 2025

Unicycive Therapeutics - The Pharma Letter

Jul 02, 2025
pulisher
Jul 02, 2025

Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN

Jul 02, 2025
pulisher
Jul 02, 2025

Ongoing Unicycive Therapeutics, Inc. (UNCY) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire

Jul 02, 2025

Unicycive Therapeutics Inc Azioni (UNCY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):